MX366164B - Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. - Google Patents

Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Info

Publication number
MX366164B
MX366164B MX2017013491A MX2017013491A MX366164B MX 366164 B MX366164 B MX 366164B MX 2017013491 A MX2017013491 A MX 2017013491A MX 2017013491 A MX2017013491 A MX 2017013491A MX 366164 B MX366164 B MX 366164B
Authority
MX
Mexico
Prior art keywords
prostate cancer
test
gene expression
expression profile
determining prognosis
Prior art date
Application number
MX2017013491A
Other languages
English (en)
Inventor
J Pelham Robert
Crager Michael
Shak Steve
Lee Mark
Novotny William
Cherbavaz Diana
L Millward Carl
Knezevic Dejan
Maddala Tara
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX366164B publication Critical patent/MX366164B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)

Abstract

La presente invención se refiere a ensayos moleculares basados en algoritmo que implica en la medición de los niveles de expresión de los genes, o sus genes co-expresados, de una muestra biológica obtenida de un paciente con cáncer de próstata. Los genes se pueden agrupar en subconjuntos de genes funcionales para calcular un registro cuantitativo útil para predecir una probabilidad de un resultado clínico para un paciente con cáncer de próstata.
MX2017013491A 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. MX366164B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
MX366164B true MX366164B (es) 2019-07-01

Family

ID=48870540

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017013491A MX366164B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2014009283A MX351626B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014009283A MX351626B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Country Status (14)

Country Link
US (3) US8725426B2 (es)
EP (3) EP3739595A3 (es)
JP (3) JP6351112B2 (es)
AU (3) AU2013215448B2 (es)
CA (1) CA2863040C (es)
CO (1) CO7051010A2 (es)
DK (1) DK3179393T3 (es)
ES (1) ES2812105T3 (es)
HK (1) HK1201881A1 (es)
IL (3) IL233709A (es)
MX (3) MX366164B (es)
NZ (2) NZ627887A (es)
SG (3) SG11201404390WA (es)
WO (1) WO2013116144A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627887A (en) * 2012-01-31 2016-08-26 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
CN105849555B (zh) * 2013-12-18 2019-05-14 加利福尼亚太平洋生物科学股份有限公司 用于错误校正的序列读数迭代聚类
CN103695560B (zh) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 Ppp1r12a基因在结直肠癌化疗疗效判断和检测试剂盒中的应用
CN112322735A (zh) * 2014-01-16 2021-02-05 启迪公司 用于前列腺癌复发的预后的基因表达面板
WO2015131177A1 (en) * 2014-02-28 2015-09-03 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
ES2838923T3 (es) 2014-10-24 2021-07-02 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta a tratamiento usando múltiples actividades de la ruta de señalización celular
CN108064311B (zh) 2014-10-24 2022-10-28 皇家飞利浦有限公司 使用多种细胞信号传导途径活性的治疗反应的医学预后和预测
DK3210142T3 (da) 2014-10-24 2020-11-16 Koninklijke Philips Nv Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
CN108738329A (zh) * 2015-05-29 2018-11-02 皇家飞利浦有限公司 前列腺癌预后方法
EP3303618B1 (en) * 2015-05-29 2019-09-25 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3318632B8 (en) * 2015-07-01 2022-12-14 Fujita Academy Marker for heterogeneity of cancer tissue, and use thereof
WO2017029215A1 (en) 2015-08-14 2017-02-23 Koninklijke Philips N.V. Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
CA3011106A1 (en) * 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
DK3270163T3 (en) * 2016-07-15 2018-11-19 Proteomedix Ag PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
ES2914727T3 (es) * 2017-02-13 2022-06-15 Genomic Health Inc Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019082118A1 (en) * 2017-10-27 2019-05-02 King Abdullah University Of Science And Technology GRAPHIC BASED CONSTANT COLUMN DOUBLE CLASSIFICATION DEVICE AND METHOD FOR MINIMIZING GROWTH PHENOTYPE DATA
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
JP7471601B2 (ja) * 2018-01-25 2024-04-22 ソルボンヌ ウニベルシテ 分子シグネチャー及び低悪性度前立腺癌の同定のためのその使用
WO2019165021A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (zh) * 2018-07-20 2018-12-14 贵州省人民医院 一种用于前列腺癌的基因联合预后检测试剂及其制备方法
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
EP3874274B1 (en) 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
AU2020329191A1 (en) 2019-08-12 2022-03-31 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330929A1 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
ES2323220T3 (es) 2000-01-13 2009-07-09 Genentech, Inc. Polipeptidos humanos stra6.
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US20030087818A1 (en) 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2442820A1 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
WO2003050243A2 (en) 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
JP2005519606A (ja) 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
CA2498418A1 (en) 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
AU2004262369A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP5813908B2 (ja) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
JP5009787B2 (ja) 2004-05-07 2012-08-22 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇ遺伝子を単独でまたは前立腺癌中で過剰発現もしくは過少発現される他の遺伝子と組み合わせて用いる、前立腺癌を診断または治療する方法
EP1766091A4 (en) 2004-05-27 2009-03-18 Vertex Pharma BIOMARKER FOR MONITORING THE INHIBITION OF THE IMPDH PATH
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
JP2008509673A (ja) 2004-08-13 2008-04-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
EP1874471A4 (en) 2005-03-16 2008-12-10 Sidney Kimmel Cancer Ct METHOD AND COMPOSITIONS FOR PREDICTING DEATH BY CANCER AND SURVIVAL OF PROSTATE CANCER USING GENE EXPRESSION SIGNATURES
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
AU2006287175A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
EP2612870A1 (en) 2005-09-12 2013-07-10 The Regents of the University of Michigan Recurrent gene fusions in prostate cancer
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
US7695913B2 (en) 2006-01-11 2010-04-13 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
EP2029020A4 (en) 2006-06-22 2010-04-21 Wisconsin Alumni Res Found USE OF STROMA COLLAGEN IN THE DIAGNOSIS AND CHARACTERIZATION OF BREAST CANCER
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008061104A2 (en) 2006-11-13 2008-05-22 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008133877A1 (en) * 2007-04-23 2008-11-06 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009253675A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
AU2009270851A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
WO2010056993A2 (en) 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
NZ594003A (en) 2009-01-07 2012-11-30 Myriad Genetics Inc Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
NZ597655A (en) 2009-07-08 2013-05-31 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
AU2010321829B2 (en) 2009-11-23 2015-07-30 Genomic Health, Inc. Methods to predict clinical outcome of cancer
MX341866B (es) 2010-01-11 2016-09-06 Genomic Health Inc Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
NZ627887A (en) * 2012-01-31 2016-08-26 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer

Also Published As

Publication number Publication date
MX2019007814A (es) 2019-09-05
CA2863040A1 (en) 2013-08-08
NZ722902A (en) 2017-12-22
EP3739595A2 (en) 2020-11-18
EP3739595A3 (en) 2021-01-27
IL254255B (en) 2018-11-29
IL262648A (en) 2018-12-31
AU2013215448A1 (en) 2014-08-21
ES2812105T3 (es) 2021-03-16
JP2015511814A (ja) 2015-04-23
US11011252B1 (en) 2021-05-18
WO2013116144A1 (en) 2013-08-08
SG11201404390WA (en) 2014-08-28
JP2019013255A (ja) 2019-01-31
AU2018201688B2 (en) 2020-02-27
NZ627887A (en) 2016-08-26
AU2020202164A1 (en) 2020-04-16
CA2863040C (en) 2022-04-19
JP6908571B2 (ja) 2021-07-28
IL262648B (en) 2020-07-30
EP3179393A3 (en) 2017-09-13
EP3179393A2 (en) 2017-06-14
DK3179393T3 (da) 2020-07-27
SG10201605210PA (en) 2016-08-30
US8725426B2 (en) 2014-05-13
IL233709A (en) 2017-09-28
CO7051010A2 (es) 2014-09-10
US20140303002A1 (en) 2014-10-09
AU2013215448B2 (en) 2018-01-04
JP2017113008A (ja) 2017-06-29
JP6351112B2 (ja) 2018-07-04
MX351626B (es) 2017-10-23
MX2014009283A (es) 2014-09-11
IL233709A0 (en) 2014-09-30
AU2020202164B2 (en) 2022-02-10
AU2018201688A1 (en) 2018-04-05
EP2809812A1 (en) 2014-12-10
EP2809812A4 (en) 2016-01-27
IL254255A0 (en) 2017-10-31
US20130196321A1 (en) 2013-08-01
SG10201912312YA (en) 2020-02-27
HK1201881A1 (en) 2015-09-11
EP3179393B1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
BR112014025269A2 (pt) método para o prognóstico e tratamento de metástase de câncer
NZ599194A (en) Methods to predict clinical outcome of cancer
NZ723570A (en) Compositions and methods for quantifying a nucleic acid sequence in a sample
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112014023296A2 (pt) métodos para fazer tipagem de uma amostra de um paciente com hepatite b, para determinar se um paciente com hepatite b tem uma chance melhorada de um resultado positivo do tratamento da hepatite b, se um indivíduo tem uma predisposição genética para uma chance melhorada para um resultado positivo de tratamento da hepatite b, para identificar um gene, e para ensaiar quanto a presença de ácido nucleico, kit de partes ou arranjo ou microarranjo ou vetor, usos de pelo menos um polinucleotídeo isolado, de um kit de partes ou arranjo ou microarranjo ou vetor e de meios para determinar um nível de expressão de carnitina e/ou um derivado de carnitina
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
WO2013190468A3 (en) Computer-based predictor for prostate cancer
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
UA106708U (uk) Спосіб прогнозування зрощення перелому
NZ610474A (en) Methods to predict clinical outcome of cancer